Penetration of garenoxacin into lung tissues and bone in subjects undergoing lung biopsy or resection

References

• Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 1995;108:43S–52S
   Google Scholar
• Breilh D, Jougon J, Djabarouti S, et al. Diffusion of oral and intravenous 400 mg once-daily moxifloxacin into lung tissue at pharmacokinetic steady-state. J Chemother 2003;15:558–62
   PubMed Web of Science ®Google Scholar
• Fabre D, Bressolle F, Gomeni R, et al. Steady-state pharmacokinetics of ciprofloxacin in plasma from patients with nosocomial pneumonia: penetration of the bronchial mucosa. Antimicrob Agents Chemother 1991;35:2521–5
   PubMed Web of Science ®Google Scholar
• Honeybourne D, Banerjee D, Andrews J, Wise R. Concentrations of gatifloxacin in plasma and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 2001;48:63–6
   PubMed Web of Science ®Google Scholar
• Soman A, Honeybourne D, Andrews J, et al. Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy. J Antimicrob Chemother 1999;44:835–8
   PubMed Web of Science ®Google Scholar
• von Baum H, Bottcher S, Hoffman H, Sonntag H. Tissue penetration of a single dose of levofloxacin intravenously for antibiotic prophylaxis in lung surgery. J Antimicrob Chemother 2001;47:729–30
   PubMed Web of Science ®Google Scholar
• Lee LJ, Sha X, Gotfried MH, et al. Penetration of levofloxacin into lung tissue after oral administration to subjects undergoing lung biopsy or lobectomy. Pharmacotherapy 1998;18:35–41
   PubMed Web of Science ®Google Scholar
• Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766–77
   PubMed Web of Science ®Google Scholar
• Arnow P, Dien G, Sullivan J, et al. An open-label, multicenter, non-comparative study of oral BMS-284756 in the treatment of community acquired pneumonia (CAP). 41st interscience conference on antimicrobial agents and chemotherapy; 2001 December 16–19; Chicago, IL
   Google Scholar
• Forgarty C, Milanowski J, Heyder A, et al. A randomized, double-blind, multicenter study of 5 day and 10 day therapy with oral BMS-284756 in the treatment of acute exacerbation of chronic bronchitis (AECB). 41st interscience conference on antimicrobial agents and chemotherapy; 2001 December 16–19; Chicago, IL
   Google Scholar
• Jones RN, Pfaller MA, Stilwell M, and the SENTRY Antimicrobial Program Participants Group. Activity and spectrum of BMS 284756, a new des-F (6) quinolone, tested against strains of ciprofloxacin-resistant Gram-positive cocci. Diagn Microbiol Infect Dis 2001;39: 133–5
   Google Scholar
• Boswell FJ, Andrews JM, Wise R. Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae. J Antimicrob Chemother 2001;48: 446–7
   Google Scholar
• Bassetti M, Dembry LM, Farrel PA, et al. Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against Gram-positive clinical isolates. Antimicrob Agents Chemother 2002;46:234–8
   PubMed Web of Science ®Google Scholar
• Schmitz FJ, Milatovic D, Boos M, et al. In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility. J Antimicrob Chemother 2002;49:698–700
   PubMed Web of Science ®Google Scholar
• Takahata M, Mitsuyama J, Yamashiro Y, et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999;43:1077–84
   PubMed Web of Science ®Google Scholar
• Noviello S, Ianniello F, Leone S, Esposito S. Comparative activity of garenoxacin and other agents by susceptibility and time-kill testing against Staphylococcus aureus, Streptococcus pyogenes and respiratory pathogens. J Antimicrob Chemother 2003;52:869–72
   PubMed Web of Science ®Google Scholar
• Dubois J, St-Pierre C. In vitro susceptibility study of BMS-284756 against Legionella species. Diagn Microbiol Infect Dis 2001;41:79–82
   PubMed Web of Science ®Google Scholar
• Fix AM, Pfaller MA, Biedenbach DJ, et al. Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. Int J Antimicrob Agents 2001;18:141–5
   PubMed Web of Science ®Google Scholar
• Hoellman DB, Kelly LM, Jacobs MR, Appelbaum PC. Comparative antianaerobic activity of BMS 284756. Antimicrob Agents Chemother 2001;45:589–92
   PubMed Web of Science ®Google Scholar
• Malay S, Roblin PM, Reznik T, et al. In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 2002;46:517–8
   PubMed Web of Science ®Google Scholar
• Takahata M, Shimakura M, Hori R, et al. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae. Antimicrob Agents Chemother 2001;45:312–5
   PubMed Web of Science ®Google Scholar
• Bello A, Stewart C, O’Mara E, et al. Absolute oral bioavailability of garenoxacin tablets and the bioequivalence of the intravenous formulation with respect to oral tablets. 37th annual American Society of Health-System Pharmacists Midyear Clinical Meeting; 2002 December 8–12; Atlanta, GA
   Google Scholar
• Gajjar DA, Bello A, Ge Z, et al. Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects. Antimicrob Agents Chemother 2003;47:2256–63
   PubMed Web of Science ®Google Scholar
• Stewart C, Gajjar D, Bello A, et al. Safety, tolerability and pharmacokinetics of BMS-284756, a novel des-F(6)-quinolone, following 28 days of once daily oral dosing in healthy subjects. 41st interscience conference on antimicrobial agents and chemotherapy; 2001 September 22–25; Chicago, IL
   Google Scholar
• Lister PD. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones. J Antimicrob Chemother 2003;51:199–202
   PubMed Web of Science ®Google Scholar
• Andrews J, Honeybourne D, Jevons G, et al. Concentrations of garenoxacin in plasma, bronchial mucosa, alveolar macrophages and epithelial lining fluid following a single oral 600 mg dose in healthy adult subjects. J Antimicrob Chemother 2003;51:727–30
   PubMed Web of Science ®Google Scholar
• Wise R, Gee T, Marshall G, Andrews JM. Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate. Antimicrob Agents Chemother 2002;46:242–4
   PubMed Web of Science ®Google Scholar
• Toussaint B, Chedin M, Bordin G, Rodriguez AR. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography–tandem mass spectrometry. I. Laboratory-validated method. J Chromatogr A 2005;1088:32–9
   PubMed Web of Science ®Google Scholar
• Toussaint B, Chedin M, Vincent U, et al. Determination of (fluoro)quinolone antibiotic residues in pig kidney using liquid chromatography–tandem mass spectrometry. Part II: intercomparison exercise. J Chromatogr A 2005;1088:40–8
   PubMed Web of Science ®Google Scholar
• Schuler P, Zemper K, Borner K, et al. Penetration of sparfloxacin and ciprofloxacin into alveolar macrophages, epithelial lining fluid, and polymorphonuclear leucocytes. Eur Respir J 1997;10:1130–6
   PubMed Web of Science ®Google Scholar
• Bello A, Hollenbaugh D, Gajjar D, et al. Ex vivo serum protein binding of BMS-284756: impact on the unbound AUC/MIC ratio for Streptococcus pneumoniae. 41st interscience conference on antimicrobial agents and chemotherapy; 2001 September 22–25; Chicago, IL
   Google Scholar
• Fung-Tomc JC, Minassian B, Kolek B, et al. Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756. Antimicrob Agents Chemother 2000;44: 3351–6
   Google Scholar
• Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in respiratory tract Streptococcus pneumoniae isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1867–74
   PubMed Web of Science ®Google Scholar
• Zhanel GG, Palatnick L, Nichol KA, et al. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1875–81
   PubMed Web of Science ®Google Scholar